

## Disclosing material information.

<b>Date</b>	10/12/2024
<b>Name of the Listed Company</b>	Gulf Pharmaceutical Industries Julphar
<b>The Material Information</b>	SAR 300 mio investment in new pharma and biotech manufacturing facility in the Kingdom of Saudi Arabia.
<b>The expected effect of material information on the financial position and results of the company's business and operations</b>	<p>In line with the company's growth strategy in the key markets in the GCC, Julphar announces today its plan to build a state-of-the art pharma and biotech manufacturing facility in the Kingdom of Saudi Arabia. Julphar will invest around SAR 300 mio in the new facility over the next few years.</p> <p>The greenfield project will include complex biologics, sterile and general formulation drug manufacturing and will follow highest quality standards, fulfilling SFDA, EMA and USFDA guidelines. Julphar will introduce a range of complex biologics and other medications after the completion of the facility.</p> <p>The project complements Julphar's continued investment initiatives in advanced manufacturing capabilities at the company's main manufacturing campus in Ras Al Khaimah in the United Arab Emirates.</p>
<b>The financial period in which the financial impact is expected to appear</b>	The project execution is planned to be initiated in Q1 2025.

<b>The Name of the Authorized Signatory</b>	Khalid Malkawi
<b>Designation</b>	Chief Financial Officer
<b>Signature and Date</b>	10/12/2024 